Eflornithine, (S)-

Eflornithine, (S)-

SCHEMBL6779172

Cl.Cl.NCCC[C@](N)(C(=O)O)C(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ODC1

The experimentally established mechanism targets of Eflornithine, (S)-. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ODC1 known ✓ P11926 2/20 0.96
BLM P54132 3/20 1.00
LMNA P02545 3/20 1.00
KDM4E B2RXH2 1/20 1.00
MAPT P10636 1/20 1.00
RAB9A P51151 1/20 1.00
PMP22 Q01453 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
ARG1 P05089 3/20 0.61
ARG2 P78540 2/20 0.40
NPSR1 Q6W5P4 2/20 0.35
THRB P10828 2/20 0.33
KMT2A Q03164 2/20 0.33
GABRR3 A8MPY1 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
HDAC3 O15379 1/20 0.33
GABBR2 O75899 1/20 0.33
CYP1A2 P05177 1/20 0.33
GABRA1 P14867 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eflornithine, (S)- SCHEMBL1322403 1.00 BLM (1.00) BLMLMNAKDM4EMAPTRAB9A
Eflornithine SCHEMBL3022583 1.00 BLM (1.00) BLMLMNAKDM4EMAPTRAB9A
D-Eflornithine SCHEMBL7208883 1.00 BLM (1.00) BLMLMNAKDM4EMAPTRAB9A
D-Eflornithine SCHEMBL6779173 1.00 BLM (1.00) BLMLMNAKDM4EMAPTRAB9A
Eflornithine SCHEMBL6779168 1.00 BLM (1.00) BLMLMNAKDM4EMAPTRAB9A
Eflornithine SCHEMBL5051665 0.98 BLM (0.96) BLMLMNAKDM4EMAPTRAB9A
Eflornithine SCHEMBL4510 0.98 BLM (0.96) BLMLMNAKDM4EMAPTRAB9A
Eflornithine SCHEMBL1397750 0.98 BLM (0.96) BLMLMNAKDM4EMAPTRAB9A
Eflornithine SCHEMBL4809264 0.98 BLM (0.96) BLMLMNAKDM4EMAPTRAB9A
D-Eflornithine SCHEMBL3238104 0.98 BLM (0.96) BLMLMNAKDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730809-B2 FORMED VIA CHEMICAL REDUCTION AND HYDROLYSIS WITH MINIMAL USE OF HALOGENATED SOLVENTS; COMPRISES USE OF INTERMEDIATES SUCH AS ETHYL 2-BENZYLIDENEAMINO-2-DIFLUOROMETHYL-4-CYANOBUTANOATE WOMEN FIRST HEALTHCARE, INC. 2004-05-04 US claimed
US-20030083384-A1 Processes for the production of alpha-difluoromethyl ornithine (DFMO) BRISTOL-MYERS SQUIBB COMPANY TO WOMEN FIRST HEALTHCARE, INC. 2003-05-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083384-A1 Processes for the production of alpha-difluoromethyl ornithine (DFMO) ODC1, OTC, OAT ODC1 1/4885BLM 3564/4885LMNA 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.